<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="636">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04488419</url>
  </required_header>
  <id_info>
    <org_study_id>ATH-1017-AD-0201</org_study_id>
    <nct_id>NCT04488419</nct_id>
  </id_info>
  <brief_title>ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease</brief_title>
  <acronym>LIFT-AD</acronym>
  <official_title>A Randomized, Placebo-Controlled, Double-Blind Study of ATH-1017 Treatment in Subjects With Mild to Moderate Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Athira Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Athira Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate safety and efficacy of fosgonimeton (ATH-1017) in the&#xD;
      treatment of mild to moderate Alzheimer's disease with a randomized treatment duration of&#xD;
      26-weeks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is designed to evaluate safety and efficacy of ATH-1017 in mild to moderate AD&#xD;
      subjects, with double-blind, parallel-arm treatment duration of 26 weeks, and based on&#xD;
      clinical diagnostic criteria of Alzheimer's disease. Clinical efficacy is demonstrated by&#xD;
      improvement in cognition and global/functional assessments comparing treatment to placebo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 28, 2020</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, double-blind, placebo-controlled, parallel-group study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall treatment effect of ATH-1017 as reflected by the Global Statistical Test</measure>
    <time_frame>Week 26</time_frame>
    <description>The Global Statistical Test (GST) combines the scores from cognition (Alzheimer's Disease Assessment Scale-Cognitive Subscale [ADAS-Cog11]) and global impression of change (Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change [ADCS-CGIC]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cognition</measure>
    <time_frame>Week 26</time_frame>
    <description>Alzheimer's Disease Assessment Scale-Cognitive Subscale [ADAS-Cog11] (Range of 0 to 70, where 0 is least impairment and 70 is most severe impairment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression of Change</measure>
    <time_frame>Week 26</time_frame>
    <description>Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change [ADCS-CGIC] (Range of 1 to 7, where 1 is marked improvement and 7 is marked worsening)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activities of Daily Living</measure>
    <time_frame>Week 26</time_frame>
    <description>Alzheimer's Disease Cooperative Study - Activities of Daily Living, 23-item version [ADCS-ADL23] (Range of 0 to 78, where a higher score indicates greater function)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">420</enrollment>
  <condition>Alzheimer Disease</condition>
  <condition>Dementia of Alzheimer Type</condition>
  <arm_group>
    <arm_group_label>Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily subcutaneous (SC) injection of Low Dose ATH-1017</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily subcutaneous (SC) injection of High Dose ATH-1017</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Daily subcutaneous (SC) injection of Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATH-1017</intervention_name>
    <description>Daily subcutaneous (SC) injection of ATH-1017 in a pre-filled syringe</description>
    <arm_group_label>High Dose</arm_group_label>
    <arm_group_label>Low Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Daily subcutaneous (SC) injection of Placebo in a pre-filled syringe</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Age 55 to 85 years&#xD;
&#xD;
          -  Mild-to-moderate AD dementia subjects, MMSE 14-24, CDR 1 or 2 at Screening&#xD;
&#xD;
          -  Clinical diagnosis of dementia, due probably to AD, by Revised National Institute on&#xD;
             Aging-Alzheimer's Association criteria (McKhann, 2011)&#xD;
&#xD;
          -  Reliable and capable support person/caregiver&#xD;
&#xD;
          -  Treatment-free or receiving stable acetylcholinesterase inhibitor (AChEI) treatment,&#xD;
             defined as:&#xD;
&#xD;
               -  Treatment-na√Øve, OR&#xD;
&#xD;
               -  Subjects are on a stable, approved dose of an AChEI (except for donepezil at 23&#xD;
                  mg PO) for at least 3 months before Screening OR&#xD;
&#xD;
               -  Subjects who received an AChEI in the past and discontinued 4 weeks prior to&#xD;
                  Screening&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  History of significant neurologic disease, other than AD, that may affect cognition,&#xD;
             or concurrent with the onset of dementia&#xD;
&#xD;
          -  Subject has atypical variant presentation of AD, if known from medical history,&#xD;
             particularly non-amnestic AD&#xD;
&#xD;
          -  History of brain MRI scan indicative of any other significant abnormality&#xD;
&#xD;
          -  Diagnosis of severe major depressive disorder even without psychotic features.&#xD;
&#xD;
          -  Significant suicide risk&#xD;
&#xD;
          -  History within 2 years of Screening, or current diagnosis of psychosis&#xD;
&#xD;
          -  Myocardial infarction or unstable angina within the last 6 months&#xD;
&#xD;
          -  Clinically significant cardiac arrhythmia (including atrial fibrillation),&#xD;
             cardiomyopathy, or cardiac conduction defect (note: pacemaker is acceptable)&#xD;
&#xD;
          -  Subject has either hypertension or symptomatic hypotension&#xD;
&#xD;
          -  Clinically significant ECG abnormality at Screening&#xD;
&#xD;
          -  Renal insufficiency (serum creatinine &gt; 2.0 mg/dL)&#xD;
&#xD;
          -  Hepatic impairment with alanine aminotransferase or aspartate aminotransferase &gt; 2&#xD;
             times the upper limit of normal, or Child-Pugh class B and C&#xD;
&#xD;
          -  Malignant tumor within 3 years before Screening&#xD;
&#xD;
          -  Memantine in any form, combination or dosage within 4 weeks prior to Screening&#xD;
&#xD;
          -  Donepezil at 23 mg PO&#xD;
&#xD;
          -  The subject has received active amyloid or tau immunization (i.e., vaccination for&#xD;
             Alzheimer's disease) at any time, or passive immunization (i.e., monoclonal antibodies&#xD;
             for Alzheimer's disease) within 6 months of Screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hans Moebius, MD, PhD</last_name>
    <phone>425-620-8501</phone>
    <email>clinicaltrials@athira.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Xenoscience</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucia Rodriguez</last_name>
      <email>lrodriguez@xenoscience.com</email>
    </contact>
    <investigator>
      <last_name>Stephen Flitman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Banner Sun Health Research Institute</name>
      <address>
        <city>Sun City</city>
        <state>Arizona</state>
        <zip>85351</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Callan</last_name>
      <phone>623-832-6573</phone>
      <email>michael.callan@bannerhealth.com</email>
    </contact>
    <investigator>
      <last_name>Ali Atri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ATP Clinical Research, Inc</name>
      <address>
        <city>Costa Mesa</city>
        <state>California</state>
        <zip>92626</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bobby Shih</last_name>
      <phone>714-277-4472</phone>
      <email>bshih@atpcr.com</email>
    </contact>
    <investigator>
      <last_name>Gustavo Alva, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neurology Center of North Orange County</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheraz Mossa</last_name>
      <phone>714-879-7200</phone>
      <phone_ext>4</phone_ext>
      <email>smossa@neurologyoc.com</email>
    </contact>
    <investigator>
      <last_name>Kiran Bath, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mile High Research Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vicki Sudan</last_name>
      <phone>303-839-9900</phone>
      <email>vicki.sudan@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Jack Klapper, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brain Matters Research</name>
      <address>
        <city>Delray Beach</city>
        <state>Florida</state>
        <zip>33445</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Houren</last_name>
      <phone>561-374-8461</phone>
      <phone_ext>2021</phone_ext>
      <email>ahouren@ergclinical.com</email>
    </contact>
    <investigator>
      <last_name>Paayal Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neuropsychiatric Research Center of SW Florida</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristen Hibbett</last_name>
      <phone>239-766-8480</phone>
      <email>khibbett@ergclinical.com</email>
    </contact>
    <investigator>
      <last_name>Wendy Bond, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>JEM Research Institute</name>
      <address>
        <city>Lake Worth</city>
        <state>Florida</state>
        <zip>33462</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Belinda Paez Russell</last_name>
      <phone>561-968-2933</phone>
      <email>brussell@jemri.net</email>
    </contact>
    <investigator>
      <last_name>Mark Goldstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ClinCloud</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcela Magana</last_name>
      <phone>407-457-7451</phone>
      <email>mmagana@myclinicloud.com</email>
    </contact>
    <investigator>
      <last_name>Esteban Olivera, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Progressive Medical Research</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <zip>32127</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dave Bachansingh</last_name>
      <phone>386-304-7070</phone>
      <email>daveb@progressivemedicalresearch.com</email>
    </contact>
    <investigator>
      <last_name>Alexander White, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Premiere Research Institute</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Amodie</last_name>
      <phone>561-296-3838</phone>
      <email>l.amodie@palmbeachneurology.com</email>
    </contact>
    <investigator>
      <last_name>Paul Winner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>iResearch Atlanta</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katie Prowse</last_name>
      <phone>404-537-1281</phone>
      <email>info@iresearchatlanta.com</email>
    </contact>
    <investigator>
      <last_name>Kimball Johnson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>iResearch Savannah</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Lagares</last_name>
      <phone>912-744-0800</phone>
      <email>info@iresearchsavannah.com</email>
    </contact>
    <investigator>
      <last_name>Michael Mobley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hawaii Pacific Neuroscience, Memory Disorders Center &amp; Alzheimer's Research</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ena Zhu</last_name>
      <phone>808-261-4476</phone>
      <email>info@hawaiineuroscience.com</email>
    </contact>
    <investigator>
      <last_name>Kore Liow, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rush Alzheimer's Disease Center, Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Yurko</last_name>
      <phone>312-942-0050</phone>
      <email>Erin_Yurko@rush.edu</email>
    </contact>
    <investigator>
      <last_name>Raj Shah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SIU Medicine Neuroscience Institute (NSI)</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Boarman</last_name>
      <phone>217-545-6829</phone>
      <email>sboarman93@siumed.edu</email>
    </contact>
    <investigator>
      <last_name>Thomas Ala, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IU Health Neuroscience Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lindsay Strickler</last_name>
      <phone>317-962-2309</phone>
      <email>lindstri@iu.edu</email>
    </contact>
    <investigator>
      <last_name>Jared Brosch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northern Light Acadia Hospital</name>
      <address>
        <city>Bangor</city>
        <state>Maine</state>
        <zip>04401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denise Michaud</last_name>
      <phone>207-973-7175</phone>
      <email>dmichaud@northernlight.org</email>
    </contact>
    <investigator>
      <last_name>Clifford Singer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Charlestown</city>
        <state>Massachusetts</state>
        <zip>02129</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abigail Watson</last_name>
      <email>awatson@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Steven Arnold, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Activmed Practices &amp; Research, Inc.</name>
      <address>
        <city>Lowell</city>
        <state>Massachusetts</state>
        <zip>01852</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Doherty</last_name>
      <phone>978-655-7155</phone>
      <email>nicole.doherty@activmedresearch.com</email>
    </contact>
    <investigator>
      <last_name>Arya Farahmand, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston Center for Memory</name>
      <address>
        <city>Newton</city>
        <state>Massachusetts</state>
        <zip>02459</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meena Huh</last_name>
      <phone>617-699-6927</phone>
      <email>meena@bostonmemory.com</email>
    </contact>
    <investigator>
      <last_name>Paul Solomon, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research Professionals</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63005</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Malana Kanallakan</last_name>
      <phone>314-328-6466</phone>
      <email>recruitment@clinicalresearchprofessionals.net</email>
    </contact>
    <investigator>
      <last_name>Siddharth Kaul, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Lou Ruvo Center for Brain Health</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meagan Jensen</last_name>
      <phone>702-701-7944</phone>
      <email>jensenm2@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Aaron Ritter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hackensack Meridian Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Domenica Vapore</last_name>
      <phone>551-996-5565</phone>
      <email>domenica.vapore@hmhn.org</email>
    </contact>
    <investigator>
      <last_name>Manisha Parulekar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Global Medical Institutes LLC; Princeton Medical Institute</name>
      <address>
        <city>Princeton</city>
        <state>New Jersey</state>
        <zip>08540</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Priya Patel</last_name>
      <phone>609-921-3551</phone>
      <phone_ext>110</phone_ext>
      <email>ppatel@gminstitutes.com</email>
    </contact>
    <investigator>
      <last_name>Sanjay Varma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Memory Research Institute of NJ</name>
      <address>
        <city>Toms River</city>
        <state>New Jersey</state>
        <zip>08755</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Brocco</last_name>
      <phone>732-341-9500</phone>
      <email>abrocco@amrinj.com</email>
    </contact>
    <investigator>
      <last_name>Sanjiv Sharma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Albuquerque Neuroscience Inc.</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Therese Chavez, MD</last_name>
      <phone>505-848-3773</phone>
      <email>therese.chavez@albneuro.com</email>
    </contact>
    <investigator>
      <last_name>Paula Lane, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neurological Associates of Albany</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Cavallaro</last_name>
      <phone>518-426-0575</phone>
      <email>research@naaresearch.com</email>
    </contact>
    <investigator>
      <last_name>Richard Holub, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester-AD-CARE Program</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14620</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Salem-Spencer</last_name>
      <phone>585-602-5203</phone>
      <email>Susan_Salem-spencer@urmc.rochester.edu</email>
    </contact>
    <investigator>
      <last_name>Anton Porsteinsson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Atrium Health Department of Psychiatry</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jovan Wright</last_name>
      <phone>704-355-6685</phone>
      <email>jovan.wright@atriumhealth.org</email>
    </contact>
    <investigator>
      <last_name>Oleg Tcheremissine, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke Neurology Research</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kate Beck</last_name>
      <phone>919-668-2278</phone>
      <email>kate.beck@duke.edu</email>
    </contact>
    <investigator>
      <last_name>James Burke, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AMC Research, LLC</name>
      <address>
        <city>Matthews</city>
        <state>North Carolina</state>
        <zip>28105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shereen Bolouri</last_name>
      <phone>704-364-4000</phone>
      <phone_ext>235</phone_ext>
      <email>ssbolouri@amcneurology.com</email>
    </contact>
    <investigator>
      <last_name>Mohammad Reza Bolouri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Insight Clinical Trials, LLC</name>
      <address>
        <city>Beachwood</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisa Poggi</last_name>
      <phone>216-295-1843</phone>
      <email>epoggi@insightclinicaltrials.com</email>
    </contact>
    <investigator>
      <last_name>Mark Stillman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neurology Diagnostics</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45459</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tasnim Kamil</last_name>
      <phone>937-224-8200</phone>
      <phone_ext>112</phone_ext>
      <email>tasnim.kamil@neurologydiagnostics.com</email>
    </contact>
    <investigator>
      <last_name>Joel Vandersluis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neurobehavioral Clinical Research</name>
      <address>
        <city>North Canton</city>
        <state>Ohio</state>
        <zip>44720</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Crystal Blackford</last_name>
      <phone>330-493-1118</phone>
      <email>cblackford@nb-cr.com</email>
    </contact>
    <investigator>
      <last_name>Shishuka Malhotra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Summit Research Network Inc.</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tawnya Andersen</last_name>
      <phone>503-228-2273</phone>
      <email>tandersen@summitnetwork.com</email>
    </contact>
    <investigator>
      <last_name>Scott Losk, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for Cognitive Health</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shelby Kline</last_name>
      <phone>503-548-0909</phone>
      <email>shelby@centerforcognitivehealth.com</email>
    </contact>
    <investigator>
      <last_name>Michael Mega, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Keystone Clinical Studies</name>
      <address>
        <city>Norristown</city>
        <state>Pennsylvania</state>
        <zip>19462</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Glick</last_name>
      <phone>610-277-8073</phone>
      <email>rachel.glick@keystoneclinicalstudies.com</email>
    </contact>
    <investigator>
      <last_name>Cherian Verghese, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rhode Island Mood &amp; Memory Research Institute</name>
      <address>
        <city>East Providence</city>
        <state>Rhode Island</state>
        <zip>02914</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dawn Hennekey</last_name>
      <phone>401-453-8950</phone>
      <email>dhennekey@rimmri.com</email>
    </contact>
    <investigator>
      <last_name>John Stoukides, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neurology Clinical, P.C.</name>
      <address>
        <city>Cordova</city>
        <state>Tennessee</state>
        <zip>38018</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Phillip Price</last_name>
      <phone>901-300-2755</phone>
      <email>pprice@neuroclinic.org</email>
    </contact>
    <investigator>
      <last_name>Thomas Arnold, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Senior Adults Specialty Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>98757</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meredith Barron</last_name>
      <phone>512-407-8628</phone>
      <email>mbarron@senioradults.net</email>
    </contact>
    <investigator>
      <last_name>Jaron Winston, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Grayline Research Center</name>
      <address>
        <city>Wichita Falls</city>
        <state>Texas</state>
        <zip>76309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tonya Crosson</last_name>
      <phone>904-322-1131</phone>
      <email>tcrosson@graylinecdt.com</email>
    </contact>
    <investigator>
      <last_name>Benny Barnhart, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwest Clinical Research Center</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>425-453-0404</phone>
      <email>enroll@nwcrc.net</email>
    </contact>
    <investigator>
      <last_name>Arifulla Khan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwest Neurological</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brenna McMahill</last_name>
      <phone>509-747-5615</phone>
      <email>brenna@nwn4me.com</email>
    </contact>
    <investigator>
      <last_name>David Greeley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011 May;7(3):263-9. doi: 10.1016/j.jalz.2011.03.005. Epub 2011 Apr 21.</citation>
    <PMID>21514250</PMID>
  </reference>
  <verification_date>May 2022</verification_date>
  <study_first_submitted>July 23, 2020</study_first_submitted>
  <study_first_submitted_qc>July 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 28, 2020</study_first_posted>
  <last_update_submitted>May 12, 2022</last_update_submitted>
  <last_update_submitted_qc>May 12, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer's Disease</keyword>
  <keyword>Cognition</keyword>
  <keyword>Dementia</keyword>
  <keyword>ATH-1017</keyword>
  <keyword>LIFT AD</keyword>
  <keyword>Fosgonimeton</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

